Background The ‘Remote Assessment of Disease and Relapse – Alzheimer’s Disease’ (RADAR‐AD) study is assessing functional decline in Alzheimer’s disease (AD) using remote monitoring techniques (RMT’s). Compared to traditional pen‐and‐paper clinical assessments, RMT’s can continuously and objectively monitor function during activities of daily living (ADL), which are arguably more sensitive to the earliest stages of AD. The aim of this abstract is to compare the results of the augmented reality task ‘Altoida’, that recreates an ADL requiring spatial navigation and memory, implemented as a tablet application, between 1) healthy controls, preclinical AD and prodromal AD, and with 2) standard clinical tests for cognitive and functional decline. Method We included amyloid negative cognitively normal (healthy controls, n=10), amyloid positive cognitively normal (preclinical AD, n=7) and amyloid positive mild cognitive impaired (prodromal AD, n=4) participants (Table 1) from the RADAR‐AD study. The outcome of the Altoida test, consisting of a motor task and two tasks in which participants have to hide‐and‐seek virtual objects, is the validated Neuromotor Index (NMI), with higher scores reflecting normative scoring, according to age, sex and education. Cognition was measured using a word‐list‐learning test, digit symbol substitution test (DSST), Rey complex figure, verbal fluency and Boston naming test. Functional decline was assessed using the Amsterdam Instrumented Activities of Daily Living (AIADL) questionnaire. Result In our preliminary sub‐sample, healthy controls showed higher NMI scores compared to the preclinical AD and prodromal AD participants (p=0.02) (Figure 1). The NMI was related to the DSST only (Figure 2). Conclusion NMI scores differed between cognitively normal healthy controls and cognitively normal preclinical AD participants, while no differences could be found in cognitive and functional tests between these groups. The sample size will increase in the coming months, but despite the currently small sample, the preliminary results are promising in evidencing that digital biomarkers are potentially more sensitive than standard clinical tests in detecting the early stages of AD, which could be helpful in developing new endpoints in clinical trials. This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking RADAR‐AD (grant No 806999) and their associated partners.
Background Diagnostic accuracy for the early detection of mild cognitive impairment (MCI) is critical both in the clinical and research settings. Our aim was to evaluate the diagnostic performance of the ALTOIDA‐iADL test in subjects with non‐degenerative MCI and prodromal (pAD) and mild (mAD) Alzheimer's disease. Methods ALTOIDA‐iADL is a 10‐minute administrable cognitive test, which assesses activities of daily living in the form of an augmented virtual reality game. The task consists of placing and finding virtual objects in a real environment and provides a final score (the NeuroMotor Index; NMI). The NMI is obtained by weighting multi‐modal information such as hands’ micromovements, walking bouts and speed, reaction time and navigation trajectory (among others), and represents the overall outcome of the individual task performance. Fifty‐one participants were included and classified according to cerebrospinal fluid (CSF) AD biomarkers: MCI (n = 22; age: 68.2; MMSE: 26.5), pAD (n = 15; age: 69.4; MMSE: 24.0) and mAD (n = 14; age: 70.6; MMSE: 20.7). Results The NMI allowed differentiating between subjects with absence (Aβ‐) and presence (Aβ+) of abnormalities in the amyloid biomarker (p < 0.01). Also, differences were found between the MCI group and the pAD (p < 0.01) and mAD (p < 0.01) groups (Fig. 1). ROC curves showed good diagnostic accuracy of the NMI in the discrimination between the Aβ‐ and Aβ+ (AUC = 0.777; p < 0.01), MCI and pAD (AUC = 0.781; p < 0.01) and MCI and mAD (AUC = 0.772; p < 0.01). The NMI did not discriminate between the pAD and mAD (AUC = 0.557; p = 0.61) groups (Fig. 2). The NMI correlated with CSF NfL levels (r = ‐.456; p < 0.05) and the MMSE score (r = .432; p < 0.01), showing an association with the degree of cognitive impairment. Conclusions ALTOIDA‐iADL is useful in the differential diagnosis between patients with non‐degenerative MCI and prodromal and mild Alzheimer's disease. Its performance is related to the degree of impairment in cognitive screening tests and with biomarkers of axonal damage/neurodegeneration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.